Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
| ▸ | NAAA | Q02083 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20168851 | 1.00 | CTSD (0.67) | CTSDLMNAMAPK1CES2CES1 | |
| SCHEMBL2978269 | 1.00 | CTSD (0.67) | CTSDLMNAMAPK1CES2CES1 | |
| SCHEMBL28711758 | 0.82 | LMNA (0.52) | CTSDLMNAMAPK1CES2CES1 | |
| SCHEMBL28711757 | 0.82 | LMNA (0.52) | CTSDLMNAMAPK1CES2CES1 | |
| SCHEMBL28065878 | 0.81 | LMNA (0.56) | CTSDLMNAMAPK1CES2CES1 | |
| SCHEMBL23358392 | 0.80 | HDAC1 (0.65) | CTSDLMNAMAPK1CES2CES1 | |
| SCHEMBL8080269 | 0.80 | HDAC1 (0.65) | CTSDLMNAMAPK1CES2CES1 | |
| SCHEMBL744074 | 0.80 | CTSD (1.00) | CTSDGAAHDAC3HDAC4HDAC1 | |
| SCHEMBL31458534 | 0.80 | CTSD (0.69) | CTSDLMNAMAPK1CES2CES1 | |
| SCHEMBL9059780 | 0.79 | LMNA (0.53) | CTSDLMNAMAPTNPC1HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12623408-B2 | Stereolithography with micron scale control of properties | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2026-05-12 | — | — | US | disclosed |
| CN-113493424-A | R/S-mandelic acid thioether derivatives containing 1,3, 4-oxadiazole structure and application thereof | 贵州大学 | 2021-10-12 | — | — | CN | disclosed |
| EP-3858342-A1 | ACYLHYDRAZONES FOR THE TREATMENT OF NEUROLOGICAL DISEASES | Consejo Superior de Investigaciones Científicas (CSIC) (ES) | 2021-08-04 | — | — | EP | disclosed |
| US-20210229364-A1 | STEREOLITHOGRAPHY WITH MICRON SCALE CONTROL OF PROPERTIES | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2021-07-29 | — | — | US | disclosed |
| WO-2020065119-A1 | ACYLHYDRAZONES FOR THE TREATMENT OF NEUROLOGICAL DISEASES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2020-04-02 | — | — | WO | disclosed |
| US-9867862-B2 | Compounds and method for treating or preventing disease conditions associated with alpha-1-antitrypsin | AMICUS THERAPEUTICS, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9867862-B2 | Compounds and method for treating or preventing disease conditions associated with alpha-1-antitrypsin | AMICUS THERAPEUTICS, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20150265671-A1 | COMPOUNDS AND METHODS FOR TREATING OR PREVENTING DISEASE CONDITIONS ASSOCIATED WITH ALPHA-1-ANTIRYPSIN | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-09-24 | — | — | US | disclosed |
| US-20150265671-A1 | COMPOUNDS AND METHODS FOR TREATING OR PREVENTING DISEASE CONDITIONS ASSOCIATED WITH ALPHA-1-ANTIRYPSIN | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-09-24 | — | — | US | disclosed |
| US-8993525-B2 | Compounds and methods for treating or preventing disease conditions associated with α-1-antitrypsin | AMICUS THERAPEUTICS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993525-B2 | Compounds and methods for treating or preventing disease conditions associated with α-1-antitrypsin | AMICUS THERAPEUTICS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20130252906-A1 | COMPOUNDS AND METHODS FOR TREATING OR PREVENTING DISEASE CONDITIONS ASSOCIATED WITH ALPHA-1-ANTITRYPSIN | AMICUS THERAPEUTICS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252906-A1 | COMPOUNDS AND METHODS FOR TREATING OR PREVENTING DISEASE CONDITIONS ASSOCIATED WITH ALPHA-1-ANTITRYPSIN | AMICUS THERAPEUTICS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-6825192-B1 | NON-N-METHYL-D-ASPARTATE (NON- NMDA) EXCITATORY AMINO ACID RECEPTOR ANTAGONISTIC ACTION, FOR EXAMPLE 2-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLE PROPIONIC ACID (AMPA) RECEPTOR ANTAGONISTIC ACTION | EISAI CO., LTD. (JP) | 2004-11-30 | — | — | US | disclosed |
| EP-1153922-A1 | HETERODIAZINONE DERIVATIVES | Eisai Co., Ltd. (JP) | 2001-11-14 | — | — | EP | disclosed |
| US-3972905-A | FUNGICIDE | BAYER AKTIENGESELLSCHAFT (DT) | 1976-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252906-A1 | COMPOUNDS AND METHODS FOR TREATING OR PREVENTING DISEASE CONDITIONS ASSOCIATED WITH ALPHA-1-ANTITRYPSIN | SERPINA2, SERPINA3, SERPINC1 | CTSD 1184/4885LMNA 1197/4885MAPK1 1859/4885 |
| US-20150265671-A1 | COMPOUNDS AND METHODS FOR TREATING OR PREVENTING DISEASE CONDITIONS ASSOCIATED WITH ALPHA-1-ANTIRYPSIN | SERPINA2, SERPINA3, SERPINC1 | CTSD 1141/4885LMNA 1278/4885MAPK1 1943/4885 |
| US-12623408-B2 | Stereolithography with micron scale control of properties | VCL, HTR3D, PIEZO1 | CTSD 520/4885LMNA 1090/4885MAPK1 3252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.